Loading…

Abstract LB057: Bevacizumab leaves a photoacoustic fingerprint in breast cancer mouse models

Background: Photoacoustic tomography (PAT) provides a direct readout of tumor haemoglobin (Hb) concentration and oxygenation. This readout could be used to provide an early indication of response to anti-angiogenic drugs, thus optimizing the management of these therapies. Experimental Procedures: Tw...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research (Chicago, Ill.) Ill.), 2022-06, Vol.82 (12_Supplement), p.LB057-LB057
Main Authors: Quiros-Gonzalez, Isabel, Tomaszewski, Michal R., Golinska, Monika A., Brown, Emma, Ansel-Bollepalli, Laura, Hacker, Lina, Couturier, Dominique-Laurent, Sainz, Rosa M., Bohndiek, Sarah E.
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page LB057
container_issue 12_Supplement
container_start_page LB057
container_title Cancer research (Chicago, Ill.)
container_volume 82
creator Quiros-Gonzalez, Isabel
Tomaszewski, Michal R.
Golinska, Monika A.
Brown, Emma
Ansel-Bollepalli, Laura
Hacker, Lina
Couturier, Dominique-Laurent
Sainz, Rosa M.
Bohndiek, Sarah E.
description Background: Photoacoustic tomography (PAT) provides a direct readout of tumor haemoglobin (Hb) concentration and oxygenation. This readout could be used to provide an early indication of response to anti-angiogenic drugs, thus optimizing the management of these therapies. Experimental Procedures: Two cohorts of nude Balb/c were inoculated with either estrogen-dependent MCF-7 (n=7) or estrogen-independent MDA-MB-231 (n=19) cells. Mice were randomly split into Control (Ctrl) and Bevacizumab (Bev,10 mg/Kg, IP, weekly) groups. PAT was performed weekly, starting just before enrolment. Oxy- and deoxy-Hb were quantified in the tumour and reference areas. Total Hb (THb) and O2 saturation (SO2) were calculated. Blood samples and tissues were collected after imaging. Hypoxia (Hypoxyprobe and CA-IX) and vascular density/maturity (CD31 and ASMA) were analyzed by immunohistochemistry. Circulating levels of human and mouse vascular endothelial growth factor (hVEGF and mVEGF) and Hb were measured. Summary of New Data: Reflecting clinical observations, the MCF-7 Bev group and most of the mice from the MDA-MB-231 Bev group (8/11) showed no improvement in survival with Bev treatment. All resistant tumours (Bev MCF-7 and Bev MDA-MB-231 non-responders (Bev-NR)) showed an increase in hVEGF production (Ctrl vs Bev; 73.0513.06 vs. 497103.9 for MCF-7; 247.984.81 vs. 330.4 85.97 for Bev NR). MDA-MB-231 responders (Bev-R) showed a significant decrease in hVEGF (247.984.81 vs. 80.53 26.13). These results indicate that VEGF was only successfully sequestered in a small subset of animals (3/11) and that VEGF overload might be a resistance mechanism. At the final time point, PAT showed no difference between Ctrl and Bev-NR in THb for either group (THbMDA-MB-231 7.2±1.3 vs. 5.5±1.2). THb was found significantly increased in the Bev-R group by PAT (13.9±3.3 p-valuevs.Crtl=0.0339; p-valuevs.Bev=0.0072) and biochemical measurements. SO2 showed a slight but significant decrease between Ctrl and Bev-NR (0.58±0.03 vs. 0.48±0.01). A dramatic decrease was seen in the Bev-R group (0.31±0.07) and significantly different from Ctrl and Bev-NR. SO2 was sensitive to early changes, SO2 values increased in Ctrl and Bev-NR 48h after enrolment (p-values paired t-test pCtrl= 0.0134; pNR=0.0268) while Bev-R shows a trend (p=0.0649). Analysis of SO2MSOT over time shows a significant (p
doi_str_mv 10.1158/1538-7445.AM2022-LB057
format article
fullrecord <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_1158_1538_7445_AM2022_LB057</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1158_1538_7445_AM2022_LB057</sourcerecordid><originalsourceid>FETCH-crossref_primary_10_1158_1538_7445_AM2022_LB0573</originalsourceid><addsrcrecordid>eNqdj82KAjEQhIOsoKu-gvQLjJuMRsWbiuJhvXkUQk_s0cj8SDoK7tPvjIrseS9dDd1VfCVEX8mBUnr6pfRwGk1GIz2Yb2MZx9H3QupJQ7Tfh48_e0t8Mp-llFpJ3Rb7ecLBow3wcM1gQTe07ueaYwIZ4Y0YEC6nMpRoyysHZyF1xZH8xbsigCsg8YQcwGJhyUNePVE1D5RxVzRTzJh6L-2I8Xq1W24i60tmT6mpQnL0d6OkqbuYGtPUmObZxTyohv82_gIVe1QS</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Abstract LB057: Bevacizumab leaves a photoacoustic fingerprint in breast cancer mouse models</title><source>Free E-Journal (出版社公開部分のみ)</source><creator>Quiros-Gonzalez, Isabel ; Tomaszewski, Michal R. ; Golinska, Monika A. ; Brown, Emma ; Ansel-Bollepalli, Laura ; Hacker, Lina ; Couturier, Dominique-Laurent ; Sainz, Rosa M. ; Bohndiek, Sarah E.</creator><creatorcontrib>Quiros-Gonzalez, Isabel ; Tomaszewski, Michal R. ; Golinska, Monika A. ; Brown, Emma ; Ansel-Bollepalli, Laura ; Hacker, Lina ; Couturier, Dominique-Laurent ; Sainz, Rosa M. ; Bohndiek, Sarah E.</creatorcontrib><description>Background: Photoacoustic tomography (PAT) provides a direct readout of tumor haemoglobin (Hb) concentration and oxygenation. This readout could be used to provide an early indication of response to anti-angiogenic drugs, thus optimizing the management of these therapies. Experimental Procedures: Two cohorts of nude Balb/c were inoculated with either estrogen-dependent MCF-7 (n=7) or estrogen-independent MDA-MB-231 (n=19) cells. Mice were randomly split into Control (Ctrl) and Bevacizumab (Bev,10 mg/Kg, IP, weekly) groups. PAT was performed weekly, starting just before enrolment. Oxy- and deoxy-Hb were quantified in the tumour and reference areas. Total Hb (THb) and O2 saturation (SO2) were calculated. Blood samples and tissues were collected after imaging. Hypoxia (Hypoxyprobe and CA-IX) and vascular density/maturity (CD31 and ASMA) were analyzed by immunohistochemistry. Circulating levels of human and mouse vascular endothelial growth factor (hVEGF and mVEGF) and Hb were measured. Summary of New Data: Reflecting clinical observations, the MCF-7 Bev group and most of the mice from the MDA-MB-231 Bev group (8/11) showed no improvement in survival with Bev treatment. All resistant tumours (Bev MCF-7 and Bev MDA-MB-231 non-responders (Bev-NR)) showed an increase in hVEGF production (Ctrl vs Bev; 73.0513.06 vs. 497103.9 for MCF-7; 247.984.81 vs. 330.4 85.97 for Bev NR). MDA-MB-231 responders (Bev-R) showed a significant decrease in hVEGF (247.984.81 vs. 80.53 26.13). These results indicate that VEGF was only successfully sequestered in a small subset of animals (3/11) and that VEGF overload might be a resistance mechanism. At the final time point, PAT showed no difference between Ctrl and Bev-NR in THb for either group (THbMDA-MB-231 7.2±1.3 vs. 5.5±1.2). THb was found significantly increased in the Bev-R group by PAT (13.9±3.3 p-valuevs.Crtl=0.0339; p-valuevs.Bev=0.0072) and biochemical measurements. SO2 showed a slight but significant decrease between Ctrl and Bev-NR (0.58±0.03 vs. 0.48±0.01). A dramatic decrease was seen in the Bev-R group (0.31±0.07) and significantly different from Ctrl and Bev-NR. SO2 was sensitive to early changes, SO2 values increased in Ctrl and Bev-NR 48h after enrolment (p-values paired t-test pCtrl= 0.0134; pNR=0.0268) while Bev-R shows a trend (p=0.0649). Analysis of SO2MSOT over time shows a significant (p&lt;0.0001) change in slope at 3 weeks after enrolment in the Bev-R group compared to either of the Ctrl or Bev-NR groups. Our results indicate that PAT SO2 can differentiate responders at very early stages of the treatment. Histologically, we observed fewer blood vessels but better structured in Bev-NR than in Bev-R, which showed higher vascular density and also higher levels of hypoxia makers. Statement of the Conclusions: Our results postulates PAT as a low-cost, label-free and non-invasive candidate to monitor response to Bevacizumab over time. Our results also indicate that tumours with functional vasculature may be resistant to Bevacizumab treatment. Citation Format: Isabel Quiros-Gonzalez, Michal R. Tomaszewski, Monika A. Golinska, Emma Brown, Laura Ansel-Bollepalli, Lina Hacker, Dominique-Laurent Couturier, Rosa M. Sainz, Sarah E. Bohndiek. Bevacizumab leaves a photoacoustic fingerprint in breast cancer mouse models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr LB057.</description><identifier>ISSN: 1538-7445</identifier><identifier>EISSN: 1538-7445</identifier><identifier>DOI: 10.1158/1538-7445.AM2022-LB057</identifier><language>eng</language><ispartof>Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.LB057-LB057</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27898,27899</link.rule.ids></links><search><creatorcontrib>Quiros-Gonzalez, Isabel</creatorcontrib><creatorcontrib>Tomaszewski, Michal R.</creatorcontrib><creatorcontrib>Golinska, Monika A.</creatorcontrib><creatorcontrib>Brown, Emma</creatorcontrib><creatorcontrib>Ansel-Bollepalli, Laura</creatorcontrib><creatorcontrib>Hacker, Lina</creatorcontrib><creatorcontrib>Couturier, Dominique-Laurent</creatorcontrib><creatorcontrib>Sainz, Rosa M.</creatorcontrib><creatorcontrib>Bohndiek, Sarah E.</creatorcontrib><title>Abstract LB057: Bevacizumab leaves a photoacoustic fingerprint in breast cancer mouse models</title><title>Cancer research (Chicago, Ill.)</title><description>Background: Photoacoustic tomography (PAT) provides a direct readout of tumor haemoglobin (Hb) concentration and oxygenation. This readout could be used to provide an early indication of response to anti-angiogenic drugs, thus optimizing the management of these therapies. Experimental Procedures: Two cohorts of nude Balb/c were inoculated with either estrogen-dependent MCF-7 (n=7) or estrogen-independent MDA-MB-231 (n=19) cells. Mice were randomly split into Control (Ctrl) and Bevacizumab (Bev,10 mg/Kg, IP, weekly) groups. PAT was performed weekly, starting just before enrolment. Oxy- and deoxy-Hb were quantified in the tumour and reference areas. Total Hb (THb) and O2 saturation (SO2) were calculated. Blood samples and tissues were collected after imaging. Hypoxia (Hypoxyprobe and CA-IX) and vascular density/maturity (CD31 and ASMA) were analyzed by immunohistochemistry. Circulating levels of human and mouse vascular endothelial growth factor (hVEGF and mVEGF) and Hb were measured. Summary of New Data: Reflecting clinical observations, the MCF-7 Bev group and most of the mice from the MDA-MB-231 Bev group (8/11) showed no improvement in survival with Bev treatment. All resistant tumours (Bev MCF-7 and Bev MDA-MB-231 non-responders (Bev-NR)) showed an increase in hVEGF production (Ctrl vs Bev; 73.0513.06 vs. 497103.9 for MCF-7; 247.984.81 vs. 330.4 85.97 for Bev NR). MDA-MB-231 responders (Bev-R) showed a significant decrease in hVEGF (247.984.81 vs. 80.53 26.13). These results indicate that VEGF was only successfully sequestered in a small subset of animals (3/11) and that VEGF overload might be a resistance mechanism. At the final time point, PAT showed no difference between Ctrl and Bev-NR in THb for either group (THbMDA-MB-231 7.2±1.3 vs. 5.5±1.2). THb was found significantly increased in the Bev-R group by PAT (13.9±3.3 p-valuevs.Crtl=0.0339; p-valuevs.Bev=0.0072) and biochemical measurements. SO2 showed a slight but significant decrease between Ctrl and Bev-NR (0.58±0.03 vs. 0.48±0.01). A dramatic decrease was seen in the Bev-R group (0.31±0.07) and significantly different from Ctrl and Bev-NR. SO2 was sensitive to early changes, SO2 values increased in Ctrl and Bev-NR 48h after enrolment (p-values paired t-test pCtrl= 0.0134; pNR=0.0268) while Bev-R shows a trend (p=0.0649). Analysis of SO2MSOT over time shows a significant (p&lt;0.0001) change in slope at 3 weeks after enrolment in the Bev-R group compared to either of the Ctrl or Bev-NR groups. Our results indicate that PAT SO2 can differentiate responders at very early stages of the treatment. Histologically, we observed fewer blood vessels but better structured in Bev-NR than in Bev-R, which showed higher vascular density and also higher levels of hypoxia makers. Statement of the Conclusions: Our results postulates PAT as a low-cost, label-free and non-invasive candidate to monitor response to Bevacizumab over time. Our results also indicate that tumours with functional vasculature may be resistant to Bevacizumab treatment. Citation Format: Isabel Quiros-Gonzalez, Michal R. Tomaszewski, Monika A. Golinska, Emma Brown, Laura Ansel-Bollepalli, Lina Hacker, Dominique-Laurent Couturier, Rosa M. Sainz, Sarah E. Bohndiek. Bevacizumab leaves a photoacoustic fingerprint in breast cancer mouse models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr LB057.</description><issn>1538-7445</issn><issn>1538-7445</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNqdj82KAjEQhIOsoKu-gvQLjJuMRsWbiuJhvXkUQk_s0cj8SDoK7tPvjIrseS9dDd1VfCVEX8mBUnr6pfRwGk1GIz2Yb2MZx9H3QupJQ7Tfh48_e0t8Mp-llFpJ3Rb7ecLBow3wcM1gQTe07ueaYwIZ4Y0YEC6nMpRoyysHZyF1xZH8xbsigCsg8YQcwGJhyUNePVE1D5RxVzRTzJh6L-2I8Xq1W24i60tmT6mpQnL0d6OkqbuYGtPUmObZxTyohv82_gIVe1QS</recordid><startdate>20220615</startdate><enddate>20220615</enddate><creator>Quiros-Gonzalez, Isabel</creator><creator>Tomaszewski, Michal R.</creator><creator>Golinska, Monika A.</creator><creator>Brown, Emma</creator><creator>Ansel-Bollepalli, Laura</creator><creator>Hacker, Lina</creator><creator>Couturier, Dominique-Laurent</creator><creator>Sainz, Rosa M.</creator><creator>Bohndiek, Sarah E.</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20220615</creationdate><title>Abstract LB057: Bevacizumab leaves a photoacoustic fingerprint in breast cancer mouse models</title><author>Quiros-Gonzalez, Isabel ; Tomaszewski, Michal R. ; Golinska, Monika A. ; Brown, Emma ; Ansel-Bollepalli, Laura ; Hacker, Lina ; Couturier, Dominique-Laurent ; Sainz, Rosa M. ; Bohndiek, Sarah E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-crossref_primary_10_1158_1538_7445_AM2022_LB0573</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Quiros-Gonzalez, Isabel</creatorcontrib><creatorcontrib>Tomaszewski, Michal R.</creatorcontrib><creatorcontrib>Golinska, Monika A.</creatorcontrib><creatorcontrib>Brown, Emma</creatorcontrib><creatorcontrib>Ansel-Bollepalli, Laura</creatorcontrib><creatorcontrib>Hacker, Lina</creatorcontrib><creatorcontrib>Couturier, Dominique-Laurent</creatorcontrib><creatorcontrib>Sainz, Rosa M.</creatorcontrib><creatorcontrib>Bohndiek, Sarah E.</creatorcontrib><collection>CrossRef</collection><jtitle>Cancer research (Chicago, Ill.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Quiros-Gonzalez, Isabel</au><au>Tomaszewski, Michal R.</au><au>Golinska, Monika A.</au><au>Brown, Emma</au><au>Ansel-Bollepalli, Laura</au><au>Hacker, Lina</au><au>Couturier, Dominique-Laurent</au><au>Sainz, Rosa M.</au><au>Bohndiek, Sarah E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Abstract LB057: Bevacizumab leaves a photoacoustic fingerprint in breast cancer mouse models</atitle><jtitle>Cancer research (Chicago, Ill.)</jtitle><date>2022-06-15</date><risdate>2022</risdate><volume>82</volume><issue>12_Supplement</issue><spage>LB057</spage><epage>LB057</epage><pages>LB057-LB057</pages><issn>1538-7445</issn><eissn>1538-7445</eissn><abstract>Background: Photoacoustic tomography (PAT) provides a direct readout of tumor haemoglobin (Hb) concentration and oxygenation. This readout could be used to provide an early indication of response to anti-angiogenic drugs, thus optimizing the management of these therapies. Experimental Procedures: Two cohorts of nude Balb/c were inoculated with either estrogen-dependent MCF-7 (n=7) or estrogen-independent MDA-MB-231 (n=19) cells. Mice were randomly split into Control (Ctrl) and Bevacizumab (Bev,10 mg/Kg, IP, weekly) groups. PAT was performed weekly, starting just before enrolment. Oxy- and deoxy-Hb were quantified in the tumour and reference areas. Total Hb (THb) and O2 saturation (SO2) were calculated. Blood samples and tissues were collected after imaging. Hypoxia (Hypoxyprobe and CA-IX) and vascular density/maturity (CD31 and ASMA) were analyzed by immunohistochemistry. Circulating levels of human and mouse vascular endothelial growth factor (hVEGF and mVEGF) and Hb were measured. Summary of New Data: Reflecting clinical observations, the MCF-7 Bev group and most of the mice from the MDA-MB-231 Bev group (8/11) showed no improvement in survival with Bev treatment. All resistant tumours (Bev MCF-7 and Bev MDA-MB-231 non-responders (Bev-NR)) showed an increase in hVEGF production (Ctrl vs Bev; 73.0513.06 vs. 497103.9 for MCF-7; 247.984.81 vs. 330.4 85.97 for Bev NR). MDA-MB-231 responders (Bev-R) showed a significant decrease in hVEGF (247.984.81 vs. 80.53 26.13). These results indicate that VEGF was only successfully sequestered in a small subset of animals (3/11) and that VEGF overload might be a resistance mechanism. At the final time point, PAT showed no difference between Ctrl and Bev-NR in THb for either group (THbMDA-MB-231 7.2±1.3 vs. 5.5±1.2). THb was found significantly increased in the Bev-R group by PAT (13.9±3.3 p-valuevs.Crtl=0.0339; p-valuevs.Bev=0.0072) and biochemical measurements. SO2 showed a slight but significant decrease between Ctrl and Bev-NR (0.58±0.03 vs. 0.48±0.01). A dramatic decrease was seen in the Bev-R group (0.31±0.07) and significantly different from Ctrl and Bev-NR. SO2 was sensitive to early changes, SO2 values increased in Ctrl and Bev-NR 48h after enrolment (p-values paired t-test pCtrl= 0.0134; pNR=0.0268) while Bev-R shows a trend (p=0.0649). Analysis of SO2MSOT over time shows a significant (p&lt;0.0001) change in slope at 3 weeks after enrolment in the Bev-R group compared to either of the Ctrl or Bev-NR groups. Our results indicate that PAT SO2 can differentiate responders at very early stages of the treatment. Histologically, we observed fewer blood vessels but better structured in Bev-NR than in Bev-R, which showed higher vascular density and also higher levels of hypoxia makers. Statement of the Conclusions: Our results postulates PAT as a low-cost, label-free and non-invasive candidate to monitor response to Bevacizumab over time. Our results also indicate that tumours with functional vasculature may be resistant to Bevacizumab treatment. Citation Format: Isabel Quiros-Gonzalez, Michal R. Tomaszewski, Monika A. Golinska, Emma Brown, Laura Ansel-Bollepalli, Lina Hacker, Dominique-Laurent Couturier, Rosa M. Sainz, Sarah E. Bohndiek. Bevacizumab leaves a photoacoustic fingerprint in breast cancer mouse models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr LB057.</abstract><doi>10.1158/1538-7445.AM2022-LB057</doi></addata></record>
fulltext fulltext
identifier ISSN: 1538-7445
ispartof Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.LB057-LB057
issn 1538-7445
1538-7445
language eng
recordid cdi_crossref_primary_10_1158_1538_7445_AM2022_LB057
source Free E-Journal (出版社公開部分のみ)
title Abstract LB057: Bevacizumab leaves a photoacoustic fingerprint in breast cancer mouse models
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-03-05T02%3A32%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Abstract%20LB057:%20Bevacizumab%20leaves%20a%20photoacoustic%20fingerprint%20in%20breast%20cancer%20mouse%20models&rft.jtitle=Cancer%20research%20(Chicago,%20Ill.)&rft.au=Quiros-Gonzalez,%20Isabel&rft.date=2022-06-15&rft.volume=82&rft.issue=12_Supplement&rft.spage=LB057&rft.epage=LB057&rft.pages=LB057-LB057&rft.issn=1538-7445&rft.eissn=1538-7445&rft_id=info:doi/10.1158/1538-7445.AM2022-LB057&rft_dat=%3Ccrossref%3E10_1158_1538_7445_AM2022_LB057%3C/crossref%3E%3Cgrp_id%3Ecdi_FETCH-crossref_primary_10_1158_1538_7445_AM2022_LB0573%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true